Corticotherapy response in primary IgA nephropathy

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Immunoglobulin A (IgA) nephropathy is a common cause of glomerulonephritis.
• Corticosteroids have demonstrated potential benefits in managing IgA nephropathy.
• Long-term corticosteroid use requires careful evaluation of efficacy and safety.

Purpose of the Study:

• To assess the effectiveness of a 6-month steroid treatment protocol in IgA nephropathy.
• To evaluate the impact on proteinuria and renal function.
• To determine the tolerability and safety of the steroid regimen.

Main Methods:

• Retrospective study comparing a treated group (n=12) with a control group (n=9).
• Treated group received intravenous methylprednisolone and oral prednisone for 6 months.
• Proteinuria and renal function were monitored over a 12-month follow-up period.

Main Results:

• The steroid-treated group showed a significant reduction in proteinuria at 6 and 12 months compared to baseline (p < 0.05).
• Proteinuria levels in the control group did not significantly change from baseline.
• The treated group exhibited significantly lower proteinuria and higher remission rates than the control group (p < 0.05).
• Renal function remained stable in both groups, and adverse effects were generally mild.

Conclusions:

• A 6-month course of steroid treatment is effective in reducing proteinuria in IgA nephropathy patients.
• The treatment regimen was well-tolerated, with mild adverse effects reported.
• Steroid therapy offers a viable option for managing proteinuria in IgA nephropathy over a 12-month period.